NASDAQ:BBOT BridgeBio Oncology Therapeutics Q2 2026 Earnings Report $4.16 -0.50 (-10.73%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$4.30 +0.14 (+3.37%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BridgeBio Oncology Therapeutics EPS ResultsActual EPS-$705.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABridgeBio Oncology Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABridgeBio Oncology Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) BridgeBio Oncology Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: CVS Health (CVS), Ascendis Pharma (ASND) and BridgeBio Oncology Therapeutics (BBOT)September 16, 2026 | theglobeandmail.comBridgeBio Oncology Therapeutics consensus price target cut by 13.05% to $22.55September 15, 2026 | msn.comNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.September 24 at 1:00 AM | Behind the Markets (Ad)BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS PlaybookSeptember 12, 2026 | finance.yahoo.comBBOT Reports BBO-8520 Data in NSCLC, Highlights Combination ResultsSeptember 8, 2026 | marketscreener.comMBBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant CancersSeptember 8, 2026 | globenewswire.comSee More BridgeBio Oncology Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Oncology Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Oncology Therapeutics and other key companies, straight to your email. Email Address About BridgeBio Oncology TherapeuticsBridgeBio Oncology Therapeutics (NASDAQ:BBOT). is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company seeks to address cancer-driving alterations that may be underserved by existing treatments, using targeted therapies designed to match the molecular characteristics of individual tumors. Its pipeline includes BBO-8520, an investigational KRAS G12C inhibitor designed to target both active and inactive forms of the KRAS G12C protein. The program is being evaluated for potential use in cancers such as non-small cell lung cancer and other solid tumors harboring KRAS G12C mutations. BridgeBio Oncology Therapeutics is also advancing additional targeted oncology programs, including therapies directed at other genetically defined cancer pathways. The company is part of the broader BridgeBio organization and conducts drug discovery and development activities in the United States. As a clinical-stage business, its operations are primarily focused on research, clinical testing, regulatory development and establishing partnerships or other arrangements that may support the future development and commercialization of its oncology candidates.View BridgeBio Oncology Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
